Company: CPSH
Filing Date: 2025-10-06
Form Type: 424B5
Source: 0001437749-25-030558
Chunk: 4

Company: CPS TECHNOLOGIES CORP/DE/
Filing Date: 2025-10-06
Form: 424B5
Chunk 4
---
 of the technology adoption lifecycle.

Our products are manufactured by proprietary processes we have developed including the QuicksetTM Injection Molding Process (“Quickset Process”) and the QuickCastTM Pressure Infiltration Process (“QuickCast Process”).

CPS was incorporated in Massachusetts in 1984 as Ceramics Process Systems Corporation and reincorporated in Delaware in April 1987 through a merger into a wholly owned Delaware subsidiary organized for purposes of the reincorporation. In July 1987, CPS completed our initial public offering of 1.5 million shares of our Common Stock. In March 2007, the Company changed its name from Ceramics Process Systems Corporation to CPS Technologies Corp.

CPS’ website is http://www.cpstechnologysolutions.com.

Our Corporate Information

We maintain our principal executive offices at 111 South Worcester Street, Norton, MA 02766 and our telephone number is (508) 222-0614. Our corporate website address is www.cpstechnologysolutions.com. Our website and the information contained on, or that can be accessed through, the website is not incorporated by reference in, and is not part of, this prospectus. You should not rely on any such information in making your decision whether to purchase our securities.

<div align='center'>S-2</div>

THE OFFERING

| Shares of our common stock offered by us                         |     | shares                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Shares of our common stock outstanding prior to the offering     |     | 14,529,277 shares                                                                                                                                                                                                                                                                                                                                                                                                                |
| Shares of our common stock to be outstanding after this offering |     | shares                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Option to purchase additional shares                             |     | We have granted the underwriters an option exercisable for 45 days from the date of this prospectus supplement to purchase up to an additional                  shares of common stock from us.                                                                                                                                                                                                                                  |
| Use of proceeds                                                  |     | We estimate that the net proceeds to us from this offering, after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us, will be approximately $         million (or approximately $         million if the underwriters exercise their option to purchase additional shares in full).                                                                                    |
|                                                                  |     | We currently intend to use the net proceeds from this offering for general corporate purposes, which may include working capital, capital expenditures, the repayment or refinancing of existing indebtedness and other investments. See “Use of Proceeds.”                                                                                                                                                                      |
| Indications of